Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo - 09/05/15
, David Aguilar, MD b, Matthew C. Riddle, MD c, Brian Claggett, PhD d, Rafael Diaz, MD e, Kenneth Dickstein, MD, PhD f, Hertzel C. Gerstein, MD g, Peter Johnston, MD h, Lars V. Køber, MD i, Francesca Lawson, MD h, Eldrin F. Lewis, MD d, Aldo P. Maggioni, MD j, John J.V. McMurray, MD k, Lin Ping, MD h, Jeffrey L. Probstfield, MD l, Scott D. Solomon, MD d, Jean-Claude Tardif, MD m, Yujun Wu, PhD h, Marc A. Pfeffer, MD, PhD dfor the
ELIXA Investigators
Résumé |
Background |
Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.
Methods |
ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy.
Results |
Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m2, and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events.
Conclusion |
ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk.
Le texte complet de cet article est disponible en PDF.Plan
Vol 169 - N° 5
P. 631 - mai 2015 Retour au numéro
Article précédent
- Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial
- Michelle L. O’Donoghue, Ruchira Glaser, Philip E. Aylward, Matthew A. Cavender, Adam Crisp, Keith A.A. Fox, Ian Laws, Jose L. Lopez-Sendon, P. Gabriel Steg, Pierre Theroux, Marc S. Sabatine, David A. Morrow
- Long-term effects of ischemic postconditioning on clinical outcomes: 1-year follow-up of the POST randomized trial
- Joo-Yong Hahn, Cheol Woong Yu, Hun Sik Park, Young Bin Song, Eun Kyoung Kim, Hyun Jong Lee, Jang-Whan Bae, Woo-Young Chung, Seung-Hyuk Choi, Jin-Ho Choi, Jang-Ho Bae, Kyung Joo An, Jong-Seon Park, Ju Hyeon Oh, Sang-Wook Kim, Jin-Yong Hwang, Jae Kean Ryu, Do-Sun Lim, Hyeon-Cheol Gwon
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?